Documentos de Lopes R.D. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Año de Publicación: "2022"

Subtipo de publicación

Publisher

The Lancet Respiratory Medicine(1)

Área temáticas

Enfermedades(3)

Farmacología y terapéutica(2)

Medicina y salud(2)

Fisiología humana(1)

Problemas sociales y servicios a grupos(1)

Área de conocimiento

Medicina interna(3)

Ensayo clínico(2)

Enfermedad cardiovascular(1)

Origen

Palabras Claves

Heart Disease Risk Factors(1)

PCSK9 inhibitors(1)

acute coronary syndrome(1)

apolipoproteins B(1)

cholesterol, LDL(1)

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

Abstract: Background: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelme

Palabras claves:

Ali Z., Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Berwanger O., Bosch J.J., Choudhri S., Dans A.L., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Heenan L., Jolly S.S., Kontsevaya A., Loeb M., Lopes R.D., Pais P., Palileo-Villanueva L.M., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Abstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB

Palabras claves:

acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitors

Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.

The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges

Abstract: Background: Effective treatments for COVID-19 are urgently needed, but conducting randomized trials

Palabras claves:

Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Beresh H., Berwanger O., Bosch J.J., Chan N., Choudhri S., Dans A.L., DIaz R., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Jolly S.S., Kazmi K., Kontsevaya A., Lewis G., Loeb M., Lopes R.D., Nkeshimana M., Orlandini A., Pais P., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.